| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/05/2005 | US6914074 For therapy and prophylaxis of prostatitis or interstitial cystitis, inflammatory bowel disease, Crohn's disease, ulcerative proctitis, or colitis, prostatic hypertrophy, uterine leiomyomas, breast cancer, endometrial cancer |
| 07/05/2005 | US6914072 E.g., ajulemic acid; used for decreasing cell proliferation |
| 07/05/2005 | US6914067 Compositions and methods for the treatment of colorectal cancer |
| 07/05/2005 | US6914066 1,2-annelated quinoline derivatives |
| 07/05/2005 | US6914062 Pyrazinone derivatives |
| 07/05/2005 | US6914056 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation |
| 07/05/2005 | US6914055 Cancer therapeutic formulation having reduced toxicity comprising a galactomannan, and a chemotherapeutic agent |
| 07/05/2005 | US6914046 Administering human growth hormone having a specific amino acid sequence to cancer patients who are resistant to, or at risk of developing a resistance to a NF-kappa B-activating cytotoxic molecule |
| 07/05/2005 | US6914044 Compounds and methods for modulating cell adhesion |
| 07/05/2005 | US6913926 Use of a pituitary tumor transforming gene peptide which has the ability to regulate endogenous PTTG1 expression and/or function in a dominant negative manner |
| 07/05/2005 | US6913915 PEG-modified uricase |
| 07/05/2005 | US6913883 IGF-1 receptor interacting proteins |
| 07/05/2005 | US6913750 Therapeutic compounds structurally-linked to bacterial polypeptides |
| 07/05/2005 | US6913744 Administering collagenase and other enzymes; side effect reduction |
| 07/05/2005 | CA2327439C Combination therapy for the treatment of tumors |
| 07/05/2005 | CA2298639C Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same |
| 07/05/2005 | CA2280875C Remedies for lymphocytic tumors |
| 07/05/2005 | CA2253545C Phosphatidic acid-comprising compositions |
| 07/05/2005 | CA2220509C Fused polycyclic heterocycle derivatives |
| 07/05/2005 | CA2160928C Compounds as pde iv and tnf inhibitors |
| 07/05/2005 | CA2129663C Biosynthetic binding protein for cancer marker |
| 06/30/2005 | WO2005059172A2 Method and nucleic acids for the improved treatment of breast cell proliferative disorders |
| 06/30/2005 | WO2005058951A1 Sugar chain-lacking hepatocyte growth factor |
| 06/30/2005 | WO2005058816A1 Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours |
| 06/30/2005 | WO2005058338A1 Use of an extract of aloysia/verbena/lippia triphylla/citriodora for treating chronic and/or inflammatory diseases |
| 06/30/2005 | WO2005058337A1 Pharmaceuticals of chinese traditional medicine of treating lung cancer and preparation method thereof |
| 06/30/2005 | WO2005058336A1 Production of hop extracts having oestrogenic and antiproliferative bioactivity |
| 06/30/2005 | WO2005058245A2 Synthetic process |
| 06/30/2005 | WO2005025574A3 PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES. |
| 06/30/2005 | WO2005025494A3 Vaccine immunotherapy for immune suppressed patients |
| 06/30/2005 | WO2005004926A8 Dendritic cell infiltrativity activating composition and immune activator |
| 06/30/2005 | WO2005000852A3 Product containing at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent |
| 06/30/2005 | WO2004085388A3 Cyclic protein tyrosine kinase inhibitors |
| 06/30/2005 | WO2004035611A3 Peptides binding the phosphatase 2a protein and polynucleotides encoding same |
| 06/30/2005 | WO2004018999A3 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 06/30/2005 | WO2004002424A8 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 06/30/2005 | WO2004001381A3 Novel raag10 cell surface target and a family of antibodies recognizing that target |
| 06/30/2005 | WO2003064629A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 06/30/2005 | WO2003018611A3 Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer |
| 06/30/2005 | WO2002058698A8 Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 06/30/2005 | US20050143583 Processes for the preparation of substituted isoxazoles and 2-isoxazolines |
| 06/30/2005 | US20050143578 Compounds and methods |
| 06/30/2005 | US20050143456 Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments |
| 06/30/2005 | US20050143455 such as (4-methyl-trans-cyclohexane-1,2-diamine)-oxalatoplatinum |
| 06/30/2005 | US20050143450 6-methyl-1,3,8-trichlorodibenzofuran; aryl hydrocarbon receptor (AhR) agonist; chemotherapy for benign and malignant prostatic hypertrophy (BPH and MPH), androgen responsive and nonresponsive neoplasm |
| 06/30/2005 | US20050143447 Mixing at least one nonaqueous, pharmaceutically acceptable solvent and a taxane compound |
| 06/30/2005 | US20050143446 Compounds for use as antigrowth agents or antitumor agents and with solvents |
| 06/30/2005 | US20050143438 N3 alkylated benzimidazole derivatives as MEk inhibitors |
| 06/30/2005 | US20050143436 N-acylamino with fused nitrogen heterocyclic ring compound; capase enzyme inhibitors; antiinflammatory agents; oral bioavailability; autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases |
| 06/30/2005 | US20050143430 Catechol bioisosteres |
| 06/30/2005 | US20050143406 Use of e.g. 2-butylamino-2-demethoxy-hypocrellin B in sonodyamic therapy to treat cancer, skin disorders, infections, autoimmune diseases |
| 06/30/2005 | US20050143401 Anticancer agents; (4-(3-Fluorobenzyloxy)-3-chlorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)ethyl)-thiazol-4-yl)-quinazolin-4-yl)-amine |
| 06/30/2005 | US20050143391 Heterocyclic amides with alpha-4 integrin antagonist activity |
| 06/30/2005 | US20050143385 Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors |
| 06/30/2005 | US20050143370 Therapeutic compounds |
| 06/30/2005 | US20050143346 Blocks the phosphorylation of ceramide and sphingosine, thereby maintaining high concentration of ceramide and sphingosine; has inhibitory activity of sphingosine kinase |
| 06/30/2005 | US20050143341 Novel substance having physiological property, method for producing the same and uses thereof |
| 06/30/2005 | US20050143315 N-[5-[[[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-4-[[[4-[(2-bromo-1-oxo-2-propenyl)amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride having radiosensitisation activity |
| 06/30/2005 | US20050143308 Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| 06/30/2005 | US20050143302 Inhibiting NF-kappa B-dependent target gene expression in a cell; fusions of a NEMO binding domain and a membrane translocation domain (third helix of antennapedia homeodomain or the HIV-1 Tat protein) |
| 06/30/2005 | US20050143284 Vaccination |
| 06/30/2005 | US20050142659 Purified populations of stem cells |
| 06/30/2005 | US20050142640 MUC-1 derived peptides |
| 06/30/2005 | US20050142635 chimeric antibodies comprising variable domain peptides, DNA codes for the antibodies, expression vectors, host cells and a process of culturing the host cells to produce the monoclonal antibodies, used for immunotherapy; nonimmunogenic |
| 06/30/2005 | US20050142625 monoclonal antibodies or antigen-binding fragments having specific binding affinity to an epitope of protein kinases polypeptides, used for the diagnosis and treatment of various kinase-related diseases in humans |
| 06/30/2005 | US20050142601 Nucleic acids encoding an enediyne polyketide synthase complex |
| 06/30/2005 | US20050142546 Assays for identifying modulators of rhomboid polypeptides |
| 06/30/2005 | US20050142535 Ogligonucleotides comprising alternating segments and uses thereof |
| 06/30/2005 | US20050142225 Stabilised pharmaceutical compositions on the basis of polyoxyethlated castor oil and method for manufacturing the same |
| 06/30/2005 | US20050142222 Boehmeria frutescens Thunberg, Boehmeria nivea or the nettle family extracts; without using of toxic organic solvents |
| 06/30/2005 | US20050142144 Epitope sequences |
| 06/30/2005 | US20050142138 Endothelial cell expression patterns |
| 06/30/2005 | US20050142115 Papilloma pseudovirus and preparation |
| 06/30/2005 | US20050142110 For diagnosis, prevention, or treatment of diseases responsive to therapy with interferon- beta; free of human serum albumin; stability |
| 06/30/2005 | US20050142069 Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
| 06/30/2005 | US20050139814 Benzofuran and benzothiophene derivatives useful in the treatmint of hyper-proliferative disorders |
| 06/30/2005 | CA2580663A1 Use of an extract of aloysia/verbena/lippia triphylla/citriodora for treating chronic and/or inflammatory diseases |
| 06/30/2005 | CA2550611A1 Use of siramesine in the treatment of cancer |
| 06/30/2005 | CA2550280A1 Pharmaceutical compositions containing platinum complexes with secondary xanthates and therapeutic uses thereof |
| 06/30/2005 | CA2550104A1 Use of a compound having two gold (i) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold (i) atoms for the treatment of cancer |
| 06/30/2005 | CA2550058A1 Pharmaceutical composition comprising a tgf-beta2 antisense oligonucleotide and a chemotherapeutic |
| 06/30/2005 | CA2549878A1 Glycosylation-deficient hepatocyte growth factor |
| 06/30/2005 | CA2549869A1 Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents |
| 06/30/2005 | CA2549852A1 Method and nucleic acids for the improved treatment of breast cell proliferative disorders |
| 06/30/2005 | CA2549728A1 3-cyano-quinoline derivatives with antiproliferative activity |
| 06/30/2005 | CA2549662A1 A method for the production of enriched hop extracts having combined oestrogenic and antiproliferative bioactivity |
| 06/30/2005 | CA2549603A1 1-n-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them |
| 06/30/2005 | CA2549589A1 Prolinylarylacetamides |
| 06/30/2005 | CA2549074A1 Glycosylated steroid derivatives with anti-migratory activity |
| 06/30/2005 | CA2548391A1 Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours |
| 06/30/2005 | CA2547635A1 A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1 |
| 06/30/2005 | CA2547196A1 Combination of (a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof |
| 06/30/2005 | CA2546979A1 A biological active blood serum, methods of producing it and uses thereof |
| 06/30/2005 | CA2546903A1 Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors |
| 06/30/2005 | CA2546636A1 Herb composition for treating lung cancer and preparation method therefof |
| 06/29/2005 | EP1548121A1 Novel physiologically active substances |
| 06/29/2005 | EP1548032A1 Kdr peptides and vaccines comprising the same |
| 06/29/2005 | EP1548028A1 Substituted type peptides of wt1 |
| 06/29/2005 | EP1548026A1 Novel depsipeptide compound |
| 06/29/2005 | EP1548015A1 Novel crystals |